JP2023523634A - 抗ウイルス性デジタルデバイス - Google Patents
抗ウイルス性デジタルデバイス Download PDFInfo
- Publication number
- JP2023523634A JP2023523634A JP2022566175A JP2022566175A JP2023523634A JP 2023523634 A JP2023523634 A JP 2023523634A JP 2022566175 A JP2022566175 A JP 2022566175A JP 2022566175 A JP2022566175 A JP 2022566175A JP 2023523634 A JP2023523634 A JP 2023523634A
- Authority
- JP
- Japan
- Prior art keywords
- subject
- exercise
- module
- tasks
- immune system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000840 anti-viral effect Effects 0.000 title description 31
- 210000000987 immune system Anatomy 0.000 claims abstract description 124
- 210000001186 vagus nerve Anatomy 0.000 claims abstract description 115
- 238000000034 method Methods 0.000 claims abstract description 111
- 230000007383 nerve stimulation Effects 0.000 claims description 95
- 230000000638 stimulation Effects 0.000 claims description 63
- 230000001953 sensory effect Effects 0.000 claims description 60
- 230000002708 enhancing effect Effects 0.000 claims description 56
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 28
- 230000033001 locomotion Effects 0.000 claims description 23
- 238000011282 treatment Methods 0.000 claims description 23
- 230000036541 health Effects 0.000 claims description 16
- 238000005728 strengthening Methods 0.000 claims description 10
- 210000003403 autonomic nervous system Anatomy 0.000 claims description 7
- 230000007384 vagal nerve stimulation Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 86
- 238000004891 communication Methods 0.000 abstract description 5
- 210000002216 heart Anatomy 0.000 description 177
- 210000001744 T-lymphocyte Anatomy 0.000 description 60
- 230000001154 acute effect Effects 0.000 description 59
- 238000012360 testing method Methods 0.000 description 50
- 241000282412 Homo Species 0.000 description 46
- 201000010099 disease Diseases 0.000 description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 40
- 230000036039 immunity Effects 0.000 description 40
- 230000003612 virological effect Effects 0.000 description 36
- 210000000822 natural killer cell Anatomy 0.000 description 29
- 239000003814 drug Substances 0.000 description 26
- 238000011160 research Methods 0.000 description 26
- 238000002255 vaccination Methods 0.000 description 26
- 210000003719 b-lymphocyte Anatomy 0.000 description 24
- 238000012216 screening Methods 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 20
- 229940079593 drug Drugs 0.000 description 20
- 241000700605 Viruses Species 0.000 description 19
- 230000001965 increasing effect Effects 0.000 description 19
- 208000024891 symptom Diseases 0.000 description 19
- 229960005486 vaccine Drugs 0.000 description 19
- 206010022000 influenza Diseases 0.000 description 18
- 230000004936 stimulating effect Effects 0.000 description 18
- 238000002560 therapeutic procedure Methods 0.000 description 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 16
- 229910052760 oxygen Inorganic materials 0.000 description 16
- 239000001301 oxygen Substances 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 15
- 102000004127 Cytokines Human genes 0.000 description 14
- 108090000695 Cytokines Proteins 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- 230000008859 change Effects 0.000 description 13
- 230000002354 daily effect Effects 0.000 description 13
- 230000028327 secretion Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 10
- 239000013264 metal-organic assembly Substances 0.000 description 10
- 206010073131 oligoastrocytoma Diseases 0.000 description 10
- 230000009385 viral infection Effects 0.000 description 10
- 230000000007 visual effect Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 230000009471 action Effects 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 230000001339 gustatory effect Effects 0.000 description 9
- 230000001939 inductive effect Effects 0.000 description 9
- 230000015788 innate immune response Effects 0.000 description 9
- 230000002503 metabolic effect Effects 0.000 description 9
- 230000003287 optical effect Effects 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 230000009184 walking Effects 0.000 description 9
- 208000036142 Viral infection Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- 238000013473 artificial intelligence Methods 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 230000002093 peripheral effect Effects 0.000 description 8
- 230000035807 sensation Effects 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 230000001276 controlling effect Effects 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 229940072221 immunoglobulins Drugs 0.000 description 7
- 238000007726 management method Methods 0.000 description 7
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 7
- 230000037081 physical activity Effects 0.000 description 7
- 210000004180 plasmocyte Anatomy 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 6
- 206010022004 Influenza like illness Diseases 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 102000003814 Interleukin-10 Human genes 0.000 description 6
- 108090000174 Interleukin-10 Proteins 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 230000006042 NK cell recruitment Effects 0.000 description 6
- 238000000692 Student's t-test Methods 0.000 description 6
- 230000003542 behavioural effect Effects 0.000 description 6
- 230000001351 cycling effect Effects 0.000 description 6
- 239000003018 immunosuppressive agent Substances 0.000 description 6
- 230000030214 innervation Effects 0.000 description 6
- 229940076144 interleukin-10 Drugs 0.000 description 6
- 230000035800 maturation Effects 0.000 description 6
- 230000000770 proinflammatory effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000012552 review Methods 0.000 description 6
- 238000012353 t test Methods 0.000 description 6
- 206010006322 Breath holding Diseases 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000003187 abdominal effect Effects 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000000222 aromatherapy Methods 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 230000007717 exclusion Effects 0.000 description 5
- 230000016784 immunoglobulin production Effects 0.000 description 5
- 229960003971 influenza vaccine Drugs 0.000 description 5
- 230000009191 jumping Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000003449 preventive effect Effects 0.000 description 5
- 210000002345 respiratory system Anatomy 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 210000002820 sympathetic nervous system Anatomy 0.000 description 5
- 238000012795 verification Methods 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 238000000729 Fisher's exact test Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 206010057190 Respiratory tract infections Diseases 0.000 description 4
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000006041 cell recruitment Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000000546 chi-square test Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 239000002955 immunomodulating agent Substances 0.000 description 4
- 229940121354 immunomodulator Drugs 0.000 description 4
- 229960003444 immunosuppressant agent Drugs 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 210000005007 innate immune system Anatomy 0.000 description 4
- 230000000366 juvenile effect Effects 0.000 description 4
- 238000009533 lab test Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 101150063569 slgA gene Proteins 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 241000711573 Coronaviridae Species 0.000 description 3
- 206010017964 Gastrointestinal infection Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 241000700647 Variola virus Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 206010001584 alcohol abuse Diseases 0.000 description 2
- 208000025746 alcohol use disease Diseases 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000011748 cell maturation Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 210000003792 cranial nerve Anatomy 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000005860 defense response to virus Effects 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000024765 knee pain Diseases 0.000 description 2
- 238000013332 literature search Methods 0.000 description 2
- 229910001416 lithium ion Inorganic materials 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000005541 medical transmission Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- QELJHCBNGDEXLD-UHFFFAOYSA-N nickel zinc Chemical compound [Ni].[Zn] QELJHCBNGDEXLD-UHFFFAOYSA-N 0.000 description 2
- 230000003950 pathogenic mechanism Effects 0.000 description 2
- 238000013439 planning Methods 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000036387 respiratory rate Effects 0.000 description 2
- 230000009183 running Effects 0.000 description 2
- 230000015541 sensory perception of touch Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 201000009032 substance abuse Diseases 0.000 description 2
- 231100000736 substance abuse Toxicity 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 229940072651 tylenol Drugs 0.000 description 2
- OBHRVMZSZIDDEK-UHFFFAOYSA-N urobilinogen Chemical compound CCC1=C(C)C(=O)NC1CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(CC3C(=C(CC)C(=O)N3)C)N2)CCC(O)=O)N1 OBHRVMZSZIDDEK-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- KTGRHKOEFSJQNS-BDQAORGHSA-N (1s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;oxalic acid Chemical compound OC(=O)C(O)=O.C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 KTGRHKOEFSJQNS-BDQAORGHSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 230000005355 Hall effect Effects 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108010015268 Integration Host Factors Proteins 0.000 description 1
- 208000015592 Involuntary movements Diseases 0.000 description 1
- KMZQAVXSMUKBPD-DJWKRKHSSA-N Lafutidine Chemical compound C=1C=COC=1C[S+]([O-])CC(=O)NC\C=C/COC(N=CC=1)=CC=1CN1CCCCC1 KMZQAVXSMUKBPD-DJWKRKHSSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 1
- 238000001347 McNemar's test Methods 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241001112090 Pseudovirus Species 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 241000287181 Sturnus vulgaris Species 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229940013181 advil Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 230000037147 athletic performance Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- OJIJEKBXJYRIBZ-UHFFFAOYSA-N cadmium nickel Chemical compound [Ni].[Cd] OJIJEKBXJYRIBZ-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000005545 community transmission Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000011217 control strategy Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 1
- 229960001971 ebastine Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 229940054157 lexapro Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000005004 lymphoid follicle Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 230000005055 memory storage Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001703 neuroimmune Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- -1 nickel metal hydride Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000001515 vagal effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/30—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4833—Assessment of subject's compliance to treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36053—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for vagal stimulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/70—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/80—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pathology (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Business, Economics & Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Business, Economics & Management (AREA)
- Surgery (AREA)
- Radiology & Medical Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Developmental Disabilities (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Social Psychology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Abstract
Description
以下、本開示内容の例示的実施形態について詳細に説明する。しかし、本開示内容は、下記で開示されている実施形態に制限されるものではなく、様々な形態に実現されることができる。以下の実施形態は、当業者が本開示内容の実施形態を実現し実施するようにするために説明される。
第1、第2などの用語は、様々な構成要素を説明するために使用されることができるが、構成要素は、このような用語に制限されない。このような用語は、一つの構成要素を他の構成要素から区別するためにのみ使用される。例えば、例示的な実施形態の範囲から逸脱せずに、第1構成要素が第2構成要素と称されることができ、同様に、第2構成要素が第1構成要素と称されることができる。「および/または(and/or)」という用語は、関連する述べられているアイテムのうち一つ以上のアイテムの任意のまたはすべての組み合わせを含む。
添付の図面を参照して、本開示内容の例示的な実施形態について下記で詳細に説明する。本開示内容の理解を容易にするために、図面の説明の全般にわたって同じ符号は同じ構成要素を指し、同じ構成要素については繰り返して説明しない。
例1:健康な成人に対する本開示内容の方法およびデバイスの効能、安全性および実現可能性を評価するための臨床試験
19歳~45歳未満の健康な成人に対して、効能、安定性および実現可能性を評価するために、シングル-センター、ランダム、オープンラベル、無-処置(no-treatment)制御、医療デバイス臨床試験が行われた。
記録が0~10秒減少/増加>0bpm
記録が10秒以上増加>-3bpm
記録が0-10秒に減少/増加>0bpm
記録が10秒以上に増加>3bpm
*10秒および3BPMは、任意に使用された。
CD4+T細胞、CD8+T細胞
B細胞
前炎症性サイトカイン(IL-6、TNF-aおよびIL-1b)、抗炎症性サイトカイン(IL-10)、IFN-γ
ウオーミングアップ:基本持続期間5分を3分に変更する。
適切な外部運動:持続期間の表示子追加(20分)
べンチマーク演習:より多い運動オプション追加(遵守度率増加)
内部活動:内部活動中の心拍数ディスプレイ
活動測定:アプリが急に終了する場合、活動記録を維持するための時間範囲(5分)を設定
今日の体調:「実行取り消し(undo)」ボタン追加
フィードバック機能:72時間アプリを使用しなかった場合、自動アラーム転送
フィードバック機能:成果率ディスプレイ
フィードバック機能:自動スケジュールアラーム挿入:D-7、D-1、D-dayポップアップメッセージが求められる。
フィードバック機能:最後の活動が完了すると、別れのあいさつ場面やポップアップウィンドウを挿入。
フィードバック機能:スケジュール進行ディスプレイ
運営システムは、患者モバイルアプリケーション(以下、「アプリ(app)」)、医者のウェブポータル、およびこの2つのチャンネルを連結するサーバを含む。
ホワイトノイズ聴取→楽なポジションで、アプリによって提供される自然のサウンドを聴取する。
呼吸中止→画面上の案内に従って30秒ごとに呼吸を中止し、それから呼吸をする。
アロマ冥想(Aroma Meditation)→キャンドルおよびディフューザといったアロマを準備した後、アプリの音声案内に従って冥想を行う。
恐怖体験→カラーによる恐怖感が提示されスクリーンを見つめる。
冷水に顔をつけること→アプリの案内に従って冷水を準備し、冷水に顔をつける。10秒間つけた後、1分30秒の休息を繰り返して5分間行う。
身体活動は、代謝当量(metabolic equivalents;METs)で測定され、ここで、1METは、静かに座るために求められるエネルギーとして定義される。適度な活動は、3~6METに対応し、高強度活動は、6MET以上に対応する。このような中強度活動を心拍数に変換することは、最大心拍数の64~76%に対応し、年齢による心拍数は、以下の数学式(単位:bpm)によって推定されることができる。
研究被験者は、以下のとおりである。
ランダム化n=42(実験群:21、対照群:21)
完了した研究被験者n=39(v4ポイント:40)
対照群:19(完了したv4:20)
19歳~50歳未満の健康な成人に対して、アプリの有能、安全性および実現可能性を評価するために、シングル-センター、ランダム、オープンラベル、無-処置制御、デジタルデバイス研究が行われた。この臨床試験の目的は、健康な成人に対して、アプリの効能、安全性および実現可能性を評価することである。この研究は、2つのグループ、すなわち、対照群と試験群で構成された。ベースラインから13週間、試験群は、モバイルアプリケーションデバイスを使用し、対照群は、アプリを使用せず、ベースラインと同じ日常を維持した。ベースラインの後、1週にインフルエンザワクチン接種が提供され、ベースライン、1週、5週および13週に血液サンプルが収集され、それぞれのグループで、また、グループの間でベースラインと比較して免疫細胞の変化を観察し、グループの間でワクチン接種日(1週)と比較して、インフルエンザ抗体生成率および力価(titer)の変化をチェックした。リサーチは、IRB承認日から12ヶ月であった。
スクリーニング前の6ヶ月内に免疫調節剤を受けたヒト、
スクリーニング前の3ヶ月以内に免疫グロブリンまたは血液-由来製品を受けたヒト
ベースラインと比較して、1週および13週での先天性免疫評価に対するNK細胞の数および活性の変化。
B細胞
前炎症性サイトカイン(IL-6、TFT-αおよびIL-1b)、抗炎症性サイトカイン(IL 10)、IFN-γ。
ワクチン接種日と比較して、5週、13週に収集された血液サンプルのインフルエンザワクチン接種後抗体生成率および抗体力価の変化。
ワクチン接種日、訪問4、訪問5でのインフルエンザ類似症状(37.8℃超の熱および咳または咽喉痛)または確認されたインフルエンザ。
順応度。
ベースラインと比較した1週、5週、13週、および25週での生活の質に対する質問票(SF-36)。
検査/訪問スケジュール。
被験者の免疫系を維持、最適化、または強化する方法として、この方法は、電子デバイスによって被験者に、第1運動モジュールおよび/または第1迷走神経刺激モジュールを提供するステップを含み、第1モジュールそれぞれは、被験者が従うべき一つ以上の第1課題を含む。
Claims (10)
- 被験者の免疫系(immune system of a subject)を維持、最適化または強化する方法であって、
電子デバイスによって被験者に、第1運動モジュールおよび/または第1迷走神経刺激モジュール(vagal nerve stimulation module)を提供するステップを含み、
前記第1モジュールそれぞれは、前記被験者が従うべき一つ以上の第1課題を含む、被験者の免疫系を維持、最適化または強化する方法。 - 前記電子デバイスによって前記被験者に、第2運動モジュールおよび/または第2迷走神経刺激モジュールを提供するステップをさらに含み、前記第2モジュールそれぞれは、一つ以上の第2課題を含み、
前記電子デバイスは、(i)前記第1モジュールの第1課題に対する前記被験者の遵守度(adherence)を感知するセンサを含み、(ii)前記遵守度に基づいて、遵守度情報をサーバに送信し、また、(iii)前記遵守度情報に基づいて、前記サーバから前記一つ以上の第2課題を受信する、請求項1に記載の被験者の免疫系を維持、最適化または強化する方法。 - 前記第1迷走神経刺激モジュールが提供され、また、前記迷走神経刺激モジュールは、視覚(sight)、聴覚(sound)、触覚(touch)、味覚(taste)および嗅覚(smell)に関する感覚刺激課題からなる群から選択される少なくとも一つの課題を含む、請求項1または請求項2に記載の被験者の免疫系を維持、最適化または強化する方法。
- 前記迷走神経刺激モジュールは、視覚に対する一つ以上の感覚刺激課題を含み、また、前記視覚に対する一つ以上の感覚刺激課題は、自律神経系(autonomic nervous system)を刺激するために、一つ以上の絵(figure)を見るための一つ以上の課題を含む、請求項3に記載の被験者の免疫系を維持、最適化または強化する方法。
- 前記第1迷走神経刺激モジュールは、触覚に対する一つ以上の感覚刺激課題を含み、また、前記触覚に対する一つ以上の感覚刺激課題は、呼吸速度(rate of breathing)を制御するための一つ以上の課題を含む、請求項1から請求項4のいずれか一項に記載の被験者の免疫系を維持、最適化または強化する方法。
- 前記センサは、タッチセンサを含み、また、前記被験者は、前記タッチセンサを使用して、前記電子デバイスに前記遵守度情報を提供する、請求項2から請求項5のいずれか一項に記載の被験者の免疫系を維持、最適化または強化する方法。
- 前記センサは、モーションセンサ(motion sensor)または加速度計(accelerometer)を含み、また、前記デバイスは、前記モーションセンサまたは前記加速度計を使用して、前記遵守度情報を検出する、請求項2から請求項6のいずれか一項に記載の被験者の免疫系を維持、最適化または強化する方法。
- 被験者の免疫系を維持、最適化または強化するためのシステムであって、
前記被験者の免疫系を維持、最適化または強化するための、第1運動モジュールおよび/または第1迷走神経刺激モジュールを含むデジタルアプリケーションを実行させるように構成された電子デバイスと、
前記デジタルアプリケーションから受信した情報に基づいて、前記被験者の免疫系を維持、最適化または強化するための治療を処方するための一つ以上の業務を行うために一つ以上のオプションをヘルスケア提供者に提供するように構成されたヘルスケア提供者ポータルと、
前記ヘルスケア提供者による前記システムに対するアクセスを管理するための一つ以上の業務を行うために、一つ以上のオプションを前記システムの管理者に提供するように構成された管理ポータル(administrative portal)とを含む、被験者の免疫系を維持、最適化または強化するためのシステム。 - 免疫系の維持、最適化または強化を要する被験者の免疫系を維持、最適化または強化するためのコンピューティングシステムであって、
前記被験者に、第1運動モジュールおよび/または第1迷走神経刺激モジュールを提供するように構成されたディスプレイ-前記第1モジュールそれぞれは、前記被験者が従うべき一つ以上の第1課題を含む-と、
遵守度情報をサーバに送信するように構成された送信機と、
前記サーバから、前記遵守度情報に基づく一つ以上の第2課題を受信するように構成された受信機と、を含み、
前記ディスプレイは、さらに、前記被験者に、第2運動モジュールおよび/または第2迷走神経刺激モジュールを提供するように構成され、前記第2モジュールそれぞれは、一つ以上の第2課題とを含む、免疫系の維持、最適化または強化を要する被験者の免疫系を維持、最適化または強化するためのコンピューティングシステム。 - 免疫系の維持、最適化または強化を要する被験者の免疫系を維持、最適化または強化するためのソフトウェア命令が保存されている非一時的コンピュータ可読媒体であって、
前記ソフトウェア命令は、プロセッサによって実行される時に、前記プロセッサにとって、
電子デバイスによって前記被験者に、第1運動モジュールおよび/または第1迷走神経刺激モジュールをディスプレイするようにし、前記第1モジュールそれぞれは、前記被験者が従うべき課題を含み、
前記電子デバイスのセンサによって、前記第1モジュールの課題に対する前記被験者の遵守度を感知するようにし、
前記電子デバイスによって、前記遵守度に基づいて、遵守度情報をサーバに送信するようにし、
前記サーバから、前記遵守度情報に基づく一つ以上の第2課題を受信するようにし、
第2運動モジュールおよび/または第2迷走神経刺激モジュールを前記被験者にディスプレイするようにし、
前記第2モジュールは、前記一つ以上の第2課題を含む、免疫系の維持、最適化または強化を要する被験者の免疫系を維持、最適化または強化するためのソフトウェア命令が保存されている非一時的コンピュータ可読媒体。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063017413P | 2020-04-29 | 2020-04-29 | |
US63/017,413 | 2020-04-29 | ||
US202063051358P | 2020-07-13 | 2020-07-13 | |
US63/051,358 | 2020-07-13 | ||
PCT/KR2021/005448 WO2021221479A1 (en) | 2020-04-29 | 2021-04-29 | Antiviral digital device |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023523634A true JP2023523634A (ja) | 2023-06-06 |
JPWO2021221479A5 JPWO2021221479A5 (ja) | 2023-06-23 |
Family
ID=78373733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022566175A Pending JP2023523634A (ja) | 2020-04-29 | 2021-04-29 | 抗ウイルス性デジタルデバイス |
Country Status (7)
Country | Link |
---|---|
US (2) | US20220115108A1 (ja) |
EP (1) | EP4143850A4 (ja) |
JP (1) | JP2023523634A (ja) |
KR (1) | KR20220161557A (ja) |
CN (1) | CN116097371A (ja) |
TW (1) | TW202211256A (ja) |
WO (2) | WO2021221479A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021221479A1 (en) * | 2020-04-29 | 2021-11-04 | S-Alpha Therapeutics, Inc. | Antiviral digital device |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100452093B1 (ko) * | 2002-02-25 | 2004-10-08 | (주)블루미디어텍 | 정신 질환 환자를 치료하기 위한 가상 환경 장치 |
US20140214135A1 (en) | 2002-05-23 | 2014-07-31 | Bio Control Medical (B.C.M.) Ltd. | Dissolvable electrode device |
US7359751B1 (en) * | 2004-05-05 | 2008-04-15 | Advanced Neuromodulation Systems, Inc. | Clinician programmer for use with trial stimulator |
JP4909156B2 (ja) | 2007-03-30 | 2012-04-04 | 富士フイルム株式会社 | 画像提示装置、画像提示方法、およびプログラム |
US20100114195A1 (en) | 2008-10-31 | 2010-05-06 | Medtronic, Inc. | Implantable medical device including extravascular cardiac stimulation and neurostimulation capabilities |
US9254383B2 (en) * | 2009-03-20 | 2016-02-09 | ElectroCore, LLC | Devices and methods for monitoring non-invasive vagus nerve stimulation |
US9248286B2 (en) | 2009-03-20 | 2016-02-02 | ElectroCore, LLC | Medical self-treatment using non-invasive vagus nerve stimulation |
US8200323B2 (en) | 2009-05-18 | 2012-06-12 | Adidas Ag | Program products, methods, and systems for providing fitness monitoring services |
US20170128356A1 (en) | 2010-11-09 | 2017-05-11 | Central Medical Technologies Inc. | Skincare stimulant having a platelet dry powder |
US9026214B2 (en) | 2011-06-23 | 2015-05-05 | Cardiac Pacemakers, Inc. | Systems and methods for avoiding aspiration during autonomic modulation therapy |
US8858414B2 (en) | 2012-02-01 | 2014-10-14 | Jason Chia-Hsien Cheng | Programmable segmented volumetric modulated arc therapy for respiratory coordination |
US20140172442A1 (en) * | 2012-10-03 | 2014-06-19 | Jeff Broderick | Systems and Methods to Assess Clinical Status and Response to Drug Therapy and Exercise |
US20150012284A1 (en) * | 2013-07-03 | 2015-01-08 | Peter Schenk | Computerized exercise equipment prescription apparatus and method |
JP6981752B2 (ja) * | 2014-05-23 | 2021-12-17 | エレクトロコア リミテッド ライアビリティ カンパニー | 迷走神経刺激システム及び方法 |
US10207150B2 (en) | 2015-02-03 | 2019-02-19 | Infinity Keyboard, Inc. | Combination therapeutic and exercise system |
US9769564B2 (en) | 2015-02-11 | 2017-09-19 | Google Inc. | Methods, systems, and media for ambient background noise modification based on mood and/or behavior information |
US20160339300A1 (en) | 2015-05-21 | 2016-11-24 | Ebay Inc. | Controlling user devices based on biometric readings |
US20160365006A1 (en) * | 2015-06-11 | 2016-12-15 | Paul Ash Minturn | Quantified Well-Being Evaluations, Improvement Programs and Scientific Wellness Video Games |
KR102446325B1 (ko) * | 2015-06-24 | 2022-09-22 | 삼성전자주식회사 | 어플리케이션 프로그램 운용 방법 및 이를 지원하는 전자 장치 |
US10709371B2 (en) | 2015-09-09 | 2020-07-14 | WellBrain, Inc. | System and methods for serving a custom meditation program to a patient |
US20170112390A1 (en) | 2015-10-22 | 2017-04-27 | Medtronic, Inc. | Atrial arrythmia detection using a pressure signal in an implantable medical device and medical system |
US9858063B2 (en) | 2016-02-10 | 2018-01-02 | Vignet Incorporated | Publishing customized application modules |
JP6944779B2 (ja) | 2016-03-08 | 2021-10-06 | 長輝 山本 | 脳機能改善のための五感機能計測および訓練システム、方法、およびプログラム |
US20170286622A1 (en) | 2016-03-29 | 2017-10-05 | International Business Machines Corporation | Patient Risk Assessment Based on Machine Learning of Health Risks of Patient Population |
US10252145B2 (en) * | 2016-05-02 | 2019-04-09 | Bao Tran | Smart device |
US11135428B2 (en) * | 2017-07-02 | 2021-10-05 | Ebt Medical, Inc. | Systems and methods for providing patient signaling and contingent stimulation |
KR102239430B1 (ko) * | 2018-10-15 | 2021-04-13 | 한국과학기술원 | 내수용 뇌파를 이용한 감정 자극 판독 방법 및 장치 |
SG11202111417UA (en) * | 2019-04-17 | 2021-11-29 | Pear Therapeutics Inc | Electronic devices and methods for treatment of depressive symptoms, depressive disorders utilizing digital therapies |
WO2021221479A1 (en) * | 2020-04-29 | 2021-11-04 | S-Alpha Therapeutics, Inc. | Antiviral digital device |
-
2021
- 2021-04-29 WO PCT/KR2021/005448 patent/WO2021221479A1/en unknown
- 2021-04-29 TW TW110115554A patent/TW202211256A/zh unknown
- 2021-04-29 EP EP21796166.3A patent/EP4143850A4/en active Pending
- 2021-04-29 KR KR1020227037721A patent/KR20220161557A/ko active IP Right Grant
- 2021-04-29 CN CN202180045572.XA patent/CN116097371A/zh active Pending
- 2021-04-29 JP JP2022566175A patent/JP2023523634A/ja active Pending
- 2021-10-27 US US17/512,579 patent/US20220115108A1/en not_active Abandoned
-
2022
- 2022-10-27 WO PCT/KR2022/016607 patent/WO2023075464A1/en active Application Filing
-
2023
- 2023-08-16 US US18/234,456 patent/US11998742B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2023075464A1 (en) | 2023-05-04 |
TW202211256A (zh) | 2022-03-16 |
US20220115108A1 (en) | 2022-04-14 |
US11998742B1 (en) | 2024-06-04 |
EP4143850A1 (en) | 2023-03-08 |
KR20220161557A (ko) | 2022-12-06 |
WO2021221479A1 (en) | 2021-11-04 |
CN116097371A (zh) | 2023-05-09 |
EP4143850A4 (en) | 2023-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10170016B2 (en) | Comprehensive management of human health | |
Helitzer et al. | A randomized controlled trial of communication training with primary care providers to improve patient-centeredness and health risk communication | |
Kim et al. | Impact of personal health records and wearables on health outcomes and patient response: three-arm randomized controlled trial | |
US20100041958A1 (en) | Computational system and method for memory modification | |
US20090312668A1 (en) | Computational system and method for memory modification | |
WO2022050293A1 (ja) | 医療システム及びそれを実行する方法 | |
US20100022820A1 (en) | Computational system and method for memory modification | |
US20100004762A1 (en) | Computational system and method for memory modification | |
US20100015583A1 (en) | Computational System and method for memory modification | |
US20100017001A1 (en) | Computational system and method for memory modification | |
US20090312595A1 (en) | System and method for memory modification | |
US20100125561A1 (en) | Computational system and method for memory modification | |
US20220168539A1 (en) | Stress reduction and sleep promotion system | |
US11998742B1 (en) | Antiviral digital device | |
Patel et al. | Effects of supervised Exercise-Based Telerehabilitation on walk test performance and quality of life in patients in India with chronic disease: Combatting Covid-19 | |
KR20240097877A (ko) | 항바이러스성 디지털 디바이스 | |
CN118318275A (en) | Antiviral digital device | |
Calvo et al. | CE Credit. Strategies To Reduce the Use of General Anesthesia for Children and Adolescents With Special Health Care Needs: Dental Desensitization and ‘Shorten the Line’Models | |
US20180113991A1 (en) | Interactive Apparatus and Devices for Personal Symptom Management and Therapeutic Treatment Systems | |
Yang et al. | Effectiveness of Home-Based Telerehabilitation Interventions for Dysphagia in Patients With Head and Neck Cancer: Systematic Review | |
Hao et al. | The application of virtual reality to home-based rehabilitation for children and adolescents with cerebral palsy: A systematic review and meta-analysis | |
Davis et al. | Developing, implementing, and evaluating personalized education for pediatric patients diagnosed with asthma on an observation unit | |
Pierz et al. | Investigation of the Impact of Wellinks on the Quality of Life and Clinical Outcomes in Patients With Chronic Obstructive Pulmonary Disease: Interventional Research Study | |
Stevens | Tailoring Physical Activity and Exercise Prescription in Children with Respiratory Diseases | |
Ringsberg et al. | Clinical health education for patients with asthma‐like symptoms but negative asthma tests |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221114 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230615 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231108 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231114 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240209 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240412 |